What immunohistochemistry (IHC) panel should be performed in an adult patient with newly diagnosed lung cancer to differentiate histologic subtypes and identify actionable alterations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Immunohistochemistry Panel for Lung Cancer Diagnosis

For newly diagnosed lung cancer, perform a minimum IHC panel of TTF-1, p40 (or p63), and Napsin A to differentiate adenocarcinoma from squamous cell carcinoma, with additional CK7 and CK5/6 reserved for equivocal cases. 1, 2

Core IHC Panel Strategy

The essential first-line panel consists of:

  • TTF-1: Primary marker for adenocarcinoma (also positive in small cell carcinoma)
  • p40: Most specific squamous cell carcinoma marker (sensitivity 84%, specificity 85%)
  • Napsin A: Highly specific adenocarcinoma marker

This 3-marker panel successfully classifies approximately 83% of morphologically ambiguous non-small cell lung cancers 2. The typical staining patterns are:

  • Adenocarcinoma: TTF-1+/Napsin A+/p40-
  • Squamous cell carcinoma: TTF-1-/Napsin A-/p40+

Managing Equivocal Results

When the initial 3-marker panel yields double-negative (all markers negative) or double-positive results, add:

  • CK7: Supports adenocarcinoma when positive
  • CK5/6: Supports squamous cell carcinoma when positive
  • p63: Alternative squamous marker (broader sensitivity than p40 but less specific)

2, 3

In double-positive cases, TTF-1 positivity is the critical discriminator favoring adenocarcinoma with 91.7% accuracy 2. In double-negative cases, p63 and/or CK5/6 positivity helps identify squamous cell carcinoma with 72.2% accuracy 2.

Approximately 85% of cases display binary staining patterns (TTF-1+/p63- or vice versa), contributing to high diagnostic accuracy 4.

Distinguishing Primary vs Metastatic Disease

When metastatic carcinoma is in the differential diagnosis, expand the panel to include:

  • CK7 and CK20: Most lung adenocarcinomas are CK7+/CK20-, while colorectal adenocarcinomas are CK7-/CK20+ 1
  • CDX-2: Positive in colorectal carcinomas, negative in lung primaries 1

The combination of TTF-1+/CK7+/CK20- strongly supports primary lung adenocarcinoma over metastatic disease from gastrointestinal sources 1.

Critical Caveats

Tissue preservation is paramount: Limit IHC testing to what is diagnostically necessary, as molecular testing for actionable mutations (EGFR, ALK, ROS1, KRAS) takes priority and requires adequate tissue 5. Studies show that 67-100% of EBUS-obtained specimens can support both IHC and molecular analysis when properly managed 5.

TTF-1 interpretation pitfalls: Remember that TTF-1 is also positive in thyroid carcinomas (papillary, follicular, medullary) and small cell lung cancer 1. Clinical correlation and additional markers are essential when thyroid metastases are considered.

Squamous cell carcinoma is TTF-1 negative: This is a defining characteristic that helps distinguish it from adenocarcinoma 1.

Morphology can be misleading: In approximately 3% of cases with seemingly classic morphology for one subtype, IHC may change the diagnosis 4. Therefore, apply IHC routinely to poorly differentiated tumors even when morphology suggests a specific subtype.

Small Cell vs Non-Small Cell Distinction

While not the primary focus of routine IHC panels, when small cell carcinoma is in the differential:

  • Small cell carcinoma is typically TTF-1+ (like adenocarcinoma)
  • Neuroendocrine markers (chromogranin, synaptophysin, CD56) confirm neuroendocrine differentiation
  • Morphology remains the primary discriminator

The accuracy of distinguishing small cell from non-small cell carcinoma exceeds 90% with appropriate sampling 5.

Practical Workflow Algorithm

  1. Start with morphologic assessment on H&E sections
  2. If adenocarcinoma vs squamous is unclear, apply TTF-1, p40, and Napsin A
  3. If results are binary (one lineage positive, other negative), diagnosis is established
  4. If double-negative or double-positive, add CK7, CK5/6, and p63
  5. If metastatic disease is suspected, add CK20 and CDX-2
  6. Reserve remaining tissue for molecular testing (EGFR, ALK, ROS1, PD-L1, etc.)

This algorithmic approach maximizes diagnostic accuracy while preserving tissue for the molecular testing that directly impacts treatment selection with targeted therapies 5, 6.

References

6
Research

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019

Related Questions

Does a patient who quit smoking 30 years ago require annual low-dose CT lung cancer screening?
What is the appropriate workup for persistent fatigue in a 64‑year‑old woman?
Are lung cancers, especially small‑cell lung carcinoma, more frequently associated with neuroendocrine paraneoplastic syndromes, and what is the underlying reason?
What is the most effective sclerosing agent for treating postoperative seromas in adults without contraindications?
In a 60-year-old man with recent small-cell lung cancer presenting with new dyspnea, tachycardia, mild hypoxemia, and no evidence of cardiac, pulmonary, or peripheral edema, what is the next appropriate diagnostic test?
What are the onset of action and time to maximal therapeutic effect of gabapentin (Neurontin)?
What is the difference between carbon dioxide retention and carbon dioxide narcosis (hypercapnic encephalopathy) and how should each be managed?
How should AVAPS (average volume‑assured pressure support) be indicated, initially set, and monitored in patients with chronic hypercapnic respiratory failure such as COPD, obesity‑hypoventilation syndrome, or neuromuscular weakness?
How should the International Personality Disorder Examination (IPDE) be administered and interpreted to assess DSM‑IV/ICD‑10 personality disorders?
What are the risks associated with enoxaparin use during pregnancy?
Is the combination of flupentixol (antipsychotic) and melitracen (antidepressant) safe in a patient with stage 4 chronic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.